Sk Biopharmaceuticals Co Ltd (326030) — Capital Reinvestment Ratio
Latest as of December 2025:
0.31x
Sk Biopharmaceuticals Co Ltd (326030) has a Capital Reinvestment Ratio of 0.31x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩87.00 Billion) in capital expenditures (₩26.55 Billion). See 326030 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.31x
Capex / Operating Cash Flow
Operating Cash Flow
₩87.00 Billion
KRW
Capital Expenditures
₩26.55 Billion
KRW
Data as of
Dec 2025
Most recent filing
Sk Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2025)
This chart tracks Sk Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd (2024–2025)
Year-by-year Capital Reinvestment Ratio for Sk Biopharmaceuticals Co Ltd from 2024 to 2025. For live market cap and broader valuation context, see 326030 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | ₩176.33 Billion | ₩29.51 Billion | ▲ +18.3% |
| 2024 | 0.14x | ₩94.90 Billion | ₩13.42 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow